9 recruiting, 6 unknown, 3 active not recruiting, 2 completed. 10 Phase 2, 8 Not applicable, 6 Phase 1, 2 Phase 3.
Follow Palliative Radiotherapy: new trials by email Literature Review of Palliative Radiotherapy trials Research Report on Palliative Radiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| High Dose Radiotherapy for Palliation (Hi-D) Palliative Radiotherapy - Metastases, Palliative Radiotherapy | Not applicable | Not yet recruiting | British Columbia Cancer Agency | 21 | 2027-03-01 | 2026-08-12 |
| Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers Stereotactic ablative radiotherapy (SABR), Palliative radiotherapy - Oligoprogression, Oligometastatic Disease | Not applicable | Recruiting | British Columbia Cancer Agency | 194 | 2025-12-04 | 2025-12-15 |
| Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC Palliative radiotherapy, Iparomlimab and tuvonralimab, TAS-102 - mCRC | Phase 2 | Not yet recruiting | Jinan Central Hospital | 37 | 2025-08-31 | 2025-08-11 |
| Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial Curcumin, Palliative radiotherapy - Cervical Cancer | Not applicable | Recruiting | Addis Ababa University | 27 | 2025-04-10 | 2025-04-20 |
| Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors Palliative radiotherapy - Gastrointestinal Cancer, Urologic Cancer | Not applicable | Recruiting | Sykehuset Telemark | 200 | 2024-12-10 | 2025-05-23 |
| Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer Biospecimen Collection, Computed Tomography, Immunotherapy - Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Active not recruiting | Mayo Clinic | 3 | 2024-11-14 | 2026-10-15 |
| Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction Biospecimen Collection, Computed Tomography, Endobronchial Ultrasound Bronchoscopy - Malignant Solid Neoplasm | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 42 | 2024-10-01 | 2026-04-06 |
| A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors BY101298 Capsules, palliative radiotherapy, curative radiotherapy - Solid Tumor, Adult | Phase 1 / Phase 2 | Terminated | Chengdu Baiyu Pharmaceutical Co., Ltd. | 60 | 2024-05-15 | 2024-12-18 |
| Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer Palliative Radiotherapy, Radical/Ablative Radiotherapy - Small Cell Lung Carcinoma | Not applicable | Recruiting | Copernicus Memorial Hospital | 165 | 2024-04-01 | 2025-08-28 |
| A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. Palliative Radiotherapy, Chemotherapy, Hormone therapy - Metastatic Tumor | Phase 3 | Recruiting | David Palma | 180 | 2023-10-06 | 2025-12-31 |
| A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue Palliative radiotherapy - Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2023-07-24 | 2026-09-02 |
| Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer Lurbinectedin, Palliative Radiation Therapy - Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 22 | 2022-07-27 | 2025-10-31 |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients XRD-0394, Palliative radiotherapy - Metastasis, Locally Advanced Solid Tumor | Phase 1 | Completed | XRad Therapeutics Inc | 12 | 2021-08-24 | 2024-01-11 |
| A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change Palliative radiotherapy - Metastatic Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2021-08-11 | 2026-05-11 |
| Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer palliative radiotherapy, Stereotactic ablative radiotherapy - Metastatic Tumors | Not applicable | Active not recruiting | British Columbia Cancer Agency | 330 | 2019-11-01 | 2026-04-29 |
| KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma KN046, palliative radiotherapy - Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Shanghai Chest Hospital | 100 | 2019-05-22 | 2019-05-29 |
| Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors Palliative Radiation, Chemotherapy, Immunotherapy - Metastatic Tumors | Phase 3 | Active not recruiting | David Palma | 204 | 2019-02-22 | 2026-09-30 |
| Prognosis of Patient Evaluated for Palliative Radiotherapy palliative radiotherapy - Cancer, Radiotherapy | Unknown | Tuen Mun Hospital | 450 | 2019-01-01 | 2019-01-09 | |
| Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer Palliative radiotherapy - Hormone-refractory Prostate Cancer | Not applicable | Unknown | Zealand University Hospital | 34 | 2018-08-01 | 2018-09-12 |
| Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC Pembrolizumab, Palliative radiotherapy - Metastatic Breast Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 8 | 2017-05-22 | 2021-04-27 |
Showing 20 of 24. Sign in to see all of them.
Neoplasm Metastasis (9) · Carcinoma, Non-Small-Cell Lung (2) · Gastrointestinal Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2) · Neoplasms (2) · Bites and Stings (1) · Breast Neoplasms (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Lobular (1) · Carcinoma, Renal Cell (1) · Esophageal Squamous Cell Carcinoma (1) · Hemorrhage (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Pain (1)
British Columbia Cancer Agency (3) · David Palma (2) · Memorial Sloan Kettering Cancer Center (2) · Addis Ababa University (1) · Chengdu Baiyu Pharmaceutical Co., Ltd. (1) · Copernicus Memorial Hospital (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Jinan Central Hospital (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mayo Clinic (1) · Melanoma and Skin Cancer Trials Limited (1) · National University Hospital, Singapore (1) · Roswell Park Cancer Institute (1) · Royal Marsden NHS Foundation Trust (1)
United States (7) · Canada (6) · Australia (4) · United Kingdom (4) · China (3) · Netherlands (2) · Switzerland (2) · Denmark (1) · Ethiopia (1) · Germany (1) · Hong Kong (1) · Ireland (1) · Norway (1) · Poland (1) · Singapore (1)
Amy Xu, MD, PhD (1) · Atif Khan, MD (1) · Biniyam Girma, Bpharm, MSc (1) · David Palma, MD (1) · David Palma, MD, PhD (1) · Dawn Owen, MD, PhD (1) · Eyasu Makonnen, Bpharm, PhD (1) · Harald Ragnum, MD,PhD (1) · Jeremy Tey, FRANZCR (1) · Jesper H Carl, Phd (1) · Kevin Harrington, MBBS MRCP FRCR (1) · Kristin Higgins, MD (1) · Martin Forster (1) · Meili Sun, Director, Department of Oncology, MD, PhD, (1) · Nathaniel Ivanick (1)
PMID 22823994, PMID 30630502, PMID 30790469, PMID 30982687, PMID 31426760, PMID 32113750, PMID 32370765, PMID 32484754, PMID 33608212, PMID 37934611, PMID 39244532, PMID 39856583, PMID 40597814
P30CA138292 (1), R01CA283547 (1)